Literature DB >> 8238491

Nanomolar ouabain augments caffeine-evoked contractions in rat arteries.

D N Weiss1, D J Podberesky, J Heidrich, M P Blaustein.   

Abstract

Chronic parenteral administration of ouabain to normal rats raises plasma ouabain concentrations to low nanomolar levels and induces hypertension [C. M. Yuan, P. Manunta, J. M. Hamlyn, S. W. Chen, E. Bohen, J. Yeun, F. J. Haddy, and M. B. Pamnani. Hypertension 22: 178-187, 1993 and see also M. P. Blaustein. Am. J. Physiol. 264 (Cell Physiol. 33): C1367-C1387, 1993]. To determine whether rat arteries are sensitive to these low ouabain levels, we tested the effects of various ouabain concentrations on caffeine-evoked contractions (CEC) in rat aortic and small mesenteric artery rings. CEC amplitude was used as a measure of the sarcoplasmic reticulum (SR) Ca2+ content. Ouabain increased CEC in aortic as well as mesenteric artery rings, but the effects in the aorta were difficult to quantitate because the CEC were often oscillatory. Mesenteric artery, under control conditions and after sensitization with 10-30 nM phenylephrine (PE), exhibited biphasic ouabain dose-CEC response curves. Low concentrations of ouabain (0.1-10 nM) caused small significant increases in CEC, but a further effect was observed only with > or = 10 microM ouabain. PE shifted the ouabain dose-response curve toward lower ouabain concentrations; conversely, ouabain shifted the PE dose-response curve toward lower PE concentrations. It appears that nanomolar concentrations of ouabain can influence vascular responsiveness to vasoconstrictors. We conclude that rat vascular smooth muscle contains both high- and low-affinity ouabain receptors, possibly corresponding to Na+ pumps with alpha 3- and alpha 1-subunit isoforms, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8238491     DOI: 10.1152/ajpcell.1993.265.5.C1443

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  Sympathetic nerves and the endothelium influence the vasoconstrictor effect of low concentrations of ouabain in pressurized small arteries.

Authors:  Hema Raina; Qingli Zhang; Albert Y Rhee; Thomas L Pallone; W Gil Wier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-09       Impact factor: 4.733

2.  Na+ pump low and high ouabain affinity alpha subunit isoforms are differently distributed in cells.

Authors:  M Juhaszova; M P Blaustein
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

Review 3.  How NaCl raises blood pressure: a new paradigm for the pathogenesis of salt-dependent hypertension.

Authors:  Mordecai P Blaustein; Frans H H Leenen; Ling Chen; Vera A Golovina; John M Hamlyn; Thomas L Pallone; James W Van Huysse; Jin Zhang; W Gil Wier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-11-04       Impact factor: 4.733

Review 4.  Endogenous ouabain: physiological activity and pathophysiological implications.

Authors:  M P Blaustein
Journal:  Clin Investig       Date:  1994-09

5.  Role of ouabain-like compound in the rostral ventrolateral medulla in rats.

Authors:  H Teruya; M Yamazato; H Muratani; A Sakima; S Takishita; Y Terano; K Fukiyama
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

6.  Cardiotonic steroids stabilize regulator of G protein signaling 2 protein levels.

Authors:  Benita Sjögren; Sergio Parra; Lauren J Heath; Kevin B Atkins; Zie-Jian Xie; Richard R Neubig
Journal:  Mol Pharmacol       Date:  2012-06-13       Impact factor: 4.436

7.  Reply: "Comment on: Endogenous Ouabain and Related Genes in the Translation from Hypertension to Renal Diseases".

Authors:  Marco Simonini; Paola Casanova; Lorena Citterio; Elisabetta Messaggio; Chiara Lanzani; Paolo Manunta
Journal:  Int J Mol Sci       Date:  2019-01-28       Impact factor: 5.923

8.  The Na,K-ATPase-Dependent Src Kinase Signaling Changes with Mesenteric Artery Diameter.

Authors:  Lin Zhang; Christian Aalkjaer; Vladimir V Matchkov
Journal:  Int J Mol Sci       Date:  2018-08-23       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.